-
公开(公告)号:US10130643B2
公开(公告)日:2018-11-20
申请号:US12955292
申请日:2010-11-29
申请人: Edward E. Cable , Mark D. Erion
发明人: Edward E. Cable , Mark D. Erion
IPC分类号: A61K31/683 , A61K31/661 , A61K31/662 , A61K31/665 , A61K31/192
摘要: The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
-
公开(公告)号:US07829552B2
公开(公告)日:2010-11-09
申请号:US10580134
申请日:2004-11-19
申请人: Mark D. Erion , Hongjian Jiang , Serge H. Boyer
发明人: Mark D. Erion , Hongjian Jiang , Serge H. Boyer
CPC分类号: C07F9/4056 , C07F9/301 , C07F9/306 , C07F9/3808 , C07F9/3882 , C07F9/4006 , C07F9/4075 , C07F9/4407 , C07F9/4465 , C07F9/5728 , C07F9/58 , C07F9/65517 , C07F9/657181
摘要: The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.
摘要翻译: 本发明涉及含有T3模拟物的膦酸化合物,其立体异构体,药学上可接受的盐,共晶体和前体药物以及前体药学上可接受的盐和共晶体,以及它们的制备和用途,用于预防和/或 治疗代谢疾病如肥胖,NASH,高胆固醇血症和高脂血症,以及相关病症如动脉粥样硬化,冠心病,糖耐量异常,代谢综合征和糖尿病。
-
公开(公告)号:US07553826B2
公开(公告)日:2009-06-30
申请号:US11582383
申请日:2006-10-18
申请人: Serge Boyer , Mark D. Erion
发明人: Serge Boyer , Mark D. Erion
IPC分类号: A61K31/661 , C07D239/20 , C07F9/6558
CPC分类号: C07F9/65742 , C07H19/04
摘要: Compounds of Formula I, their preparation and uses are described: wherein: M and V are cis to one another and MH is cytarabine; the 5′ oxygen of said cytarabine is attached to the phosphorus; V is 4-pyridyl; and pharmaceutically acceptable prodrugs and salts thereof.
摘要翻译: 描述式I化合物及其制备和用途:其中:M和V彼此是顺式的,MH是阿糖胞苷; 所述阿糖胞苷的5'氧与磷结合; V是4-吡啶基; 及其药学上可接受的前药及其盐。
-
公开(公告)号:US07514419B2
公开(公告)日:2009-04-07
申请号:US11137773
申请日:2005-05-26
申请人: Mark D. Erion , Hongjian Jiang , Serge H. Boyer
发明人: Mark D. Erion , Hongjian Jiang , Serge H. Boyer
CPC分类号: C07F9/4056 , C07F9/301 , C07F9/306 , C07F9/3808 , C07F9/3882 , C07F9/4006 , C07F9/4075 , C07F9/4407 , C07F9/4465 , C07F9/5728 , C07F9/58 , C07F9/65517 , C07F9/657181
摘要: The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.
摘要翻译: 本发明涉及含膦酸的T3模拟物及其单酯的化合物,其立体异构体,药学上可接受的盐,共晶体和前药以及其药学上可接受的盐和共结晶,以及它们的制备和用途 预防和/或治疗诸如肥胖,NASH,高胆固醇血症和高脂血症的代谢疾病,以及相关病症如动脉粥样硬化,冠心病,葡萄糖耐量降低,代谢综合症x和糖尿病。
-
公开(公告)号:US07151092B2
公开(公告)日:2006-12-19
申请号:US10698928
申请日:2003-10-31
申请人: Serge Boyer , Mark D. Erion
发明人: Serge Boyer , Mark D. Erion
IPC分类号: A61K31/665 , C07D239/22
CPC分类号: C07F9/65742 , C07H19/04
摘要: Compounds of Formula I, their preparation and uses are described: wherein: M and V are cis to one another and MH is cytarabine; the 5′ oxygen of said cytarabine is attached to the phosphorus; V is 4-pyridyl; and pharmaceutically acceptable prodrugs and salts thereof.
-
公开(公告)号:US5731432A
公开(公告)日:1998-03-24
申请号:US192154
申请日:1994-02-03
IPC分类号: A61K31/00 , A61K31/55 , A61P7/02 , A61P9/00 , A61P9/10 , A61P25/04 , A61P29/00 , A61P43/00 , C07D487/04 , C07D491/04
CPC分类号: C07D487/04 , A61K31/00 , A61K31/55
摘要: Novel diazepine derivatives which selectively inhibit adenosine monophosphate deaminase and methods of preparing these compounds are provided. These compounds are useful in treating certain conditions in vivo which may be ameliorated by increased local concentrations of adenosine.
摘要翻译: 提供选择性抑制腺苷一磷酸脱氨酶的新二氮杂衍生物及其制备方法。 这些化合物可用于治疗体内某些条件,这可以通过增加局部腺苷浓度而改善。
-
公开(公告)号:US5506347A
公开(公告)日:1996-04-09
申请号:US191282
申请日:1994-02-03
IPC分类号: C07D473/40 , A61K31/505 , A61K31/52 , A61K31/70 , A61K31/7042 , A61K31/7052 , A61K31/7076 , A61P7/02 , A61P9/00 , A61P25/00 , A61P29/00 , A61P43/00 , C07D487/04 , C07H19/04 , C07H19/06 , C07H19/14 , C07H19/16 , C07G3/00
摘要: Novel lyxose derivatives which selectively inhibit adenosine kinase and methods of preparing these compounds are provided. These compounds are useful in treating certain conditions in vivo which may be ameliorated by increased local concentrations of adenosine.
摘要翻译: 提供了选择性抑制腺苷激酶的新型赖索糖衍生物和制备这些化合物的方法。 这些化合物可用于治疗体内某些条件,这可以通过增加局部腺苷浓度而改善。
-
公开(公告)号:US08940927B2
公开(公告)日:2015-01-27
申请号:US13115647
申请日:2011-05-25
申请人: Feng Tian , Qun Dang , G. Sridhar Prasad , Wenyu Li , Brett C. Bookser , Nicholas Brian Raffaele , Mark D. Erion
发明人: Feng Tian , Qun Dang , G. Sridhar Prasad , Wenyu Li , Brett C. Bookser , Nicholas Brian Raffaele , Mark D. Erion
IPC分类号: C07F9/28 , C07C233/11 , A61K33/42 , A61K31/166 , A61P3/10 , A61P3/08 , A61P3/04 , C07F9/6558 , C07F9/38 , C07F9/40 , C07F9/58 , C07F9/6503 , C07F9/6509 , C07F9/6512 , C07F9/653 , C07F9/6539 , C07F9/6553 , C07F9/6561 , C07F9/6571
CPC分类号: C07F9/65586 , A61K31/44 , C07C233/11 , C07D213/81 , C07F9/3834 , C07F9/4021 , C07F9/58 , C07F9/65031 , C07F9/650952 , C07F9/6512 , C07F9/653 , C07F9/6539 , C07F9/65392 , C07F9/65395 , C07F9/65397 , C07F9/6541 , C07F9/655345 , C07F9/65583 , C07F9/6561 , C07F9/65616 , C07F9/657181
摘要: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinase activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
摘要翻译: 本发明提供具有葡糖激酶活化剂活性的式I和II的新化合物及其药学上可接受的盐和共结晶。 本发明进一步提供包含其的药物组合物以及治疗,预防,延迟发病时间或降低其中指示出一种或多种葡萄糖激酶激活剂的疾病或病症的发展或进展的风险的方法,包括 1型和2型糖尿病,糖耐量异常,胰岛素抵抗和高血糖。 本发明还提供了制备式I和II化合物的方法,包括其盐和共结晶,以及包含其的药物组合物。
-
公开(公告)号:US20100081634A1
公开(公告)日:2010-04-01
申请号:US11816774
申请日:2006-05-26
申请人: Mark D. Erion , Hongjian Jiang , Serge H. Boyer
发明人: Mark D. Erion , Hongjian Jiang , Serge H. Boyer
IPC分类号: A61K31/675 , A61K31/66 , C07F9/28 , C07F9/02
CPC分类号: C07F9/4056 , C07F9/301 , C07F9/306 , C07F9/3808 , C07F9/3882 , C07F9/4006 , C07F9/4075 , C07F9/4407 , C07F9/4465 , C07F9/5728 , C07F9/58 , C07F9/65517 , C07F9/657181
摘要: The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.
摘要翻译: 本发明涉及含膦酸的T3模拟物及其单酯的化合物,其立体异构体,药学上可接受的盐,共晶体和前药以及其药学上可接受的盐和共结晶,以及它们的制备和用途 预防和/或治疗诸如肥胖,NASH,高胆固醇血症和高脂血症的代谢疾病,以及相关病症如动脉粥样硬化,冠心病,葡萄糖耐量降低,代谢综合症x和糖尿病。
-
公开(公告)号:US20090232879A1
公开(公告)日:2009-09-17
申请号:US11814824
申请日:2006-05-26
申请人: Edward E. Cable , Mark D. Erion
发明人: Edward E. Cable , Mark D. Erion
IPC分类号: A61K9/70 , A61K31/19 , A61K31/662 , A61K31/675 , A61K9/48 , A61P1/16
CPC分类号: A61K31/683 , A61K31/192 , A61K31/661 , A61K31/662 , A61K31/665
摘要: The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
摘要翻译: 本发明涉及使用甲状腺受体配体的甲状霉素化合物,其药学上可接受的盐,以及这些化合物的前体药物用于预防,治疗或改善脂肪肝疾病如脂肪变性,非酒精性脂肪性肝病和 非酒精性脂肪性肝炎
-
-
-
-
-
-
-
-
-